How to take an antibody from academic discovery to the patient

Antibody, NationalCancerInstitute, Dimitrov, m102.4

Do you want to find out how to take an antibody developed in academia through clinical trials, to be administered in humans?

Dr Dimiter Dimitrov, Head of the Protein Interaction Group at the National Cancer Institute and his group have developed a therapeutic antibody against Hendra and Nipah viruses. The m102.4 was identified and characterised in an academic setting and taken through GMP production with the help of government funding – the first therapeutic of rare viral disease to take this route to patients!

Click here to view the full presentation


Do you want to find out more?

Top new results of #antibody therapeutic developments from Dr Janice Reichert

How to categorise #Antibodies

How Novartis are predicting #Antibody stability


For more updates on the vaccines industry, follow us on Twitter:  @vaccinenation or join our LinkedIn group:Vaccine Nation

Leave a Reply

Your email address will not be published. Required fields are marked *